Disclosures for "Improving Median Overall Survival (OS) of Glioblastoma (GBM) Patients by Optimizing Standard of Care (SOC) Through Multidisciplinary Team Work and Combination Therapies Including Tumor Treating Fields (TTF)"
-
Dr. Zhu has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novocure, INC, Japan. An immediate family member of Dr. Zhu has stock in Abbott lab. The institution of Dr. Zhu has received research support from NRG NIH. The institution of Dr. Zhu has received research support from Novocure, Inc. The institution of Dr. Zhu has received research support from Five Prime pharmaceutical. The institution of Dr. Zhu has received research support from Denovo, inc. The institution of Dr. Zhu has received research support from Boston Biomedical Sumitomo Dainippon Pharma Global Oncology. The institution of Dr. Zhu has received research support from CNS pharmaceutical. The institution of Dr. Zhu has received research support from ABM Therapeutics Corporation . The institution of Dr. Zhu has received research support from Chimerix Inc.
-
Dr. Chen has received personal compensation for serving as an employee of UTHealth Houston.
-
Author has nothing to disclose
-
Ms. Schumann has received personal compensation for serving as an employee of Diakonos Oncology.
-
Mrs. SINHA has nothing to disclose.
-
Miss Vu has nothing to disclose.
-
Mr. Bueno has nothing to disclose.
-
Nitin Tandon has stock in BrainDynamics. The institution of Nitin Tandon has received research support from NIH.
-
Author has nothing to disclose
-
Christian Amezquita Contreras has nothing to disclose.
-
Dr. Esquenazi has nothing to disclose.